Skip to main content
Fig. 4 | BMC Oral Health

Fig. 4

From: CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protective efficacy of the periodontitis gene vaccine in a periodontitis model in SD rats

Fig. 4

Expression levels of FimA-specific (a) and HA2-specific (b) secretory IgA antibodies in the saliva of SD rats at week 0–8, which were immunized with nothing (group A), 100 ug of saline (group B), 100 ug of pVAX1 (group C), 100 ug of pVAX1-HA2-fimA (group D), 100 ug of pVAX1-HA2-fimA/IL-15 (group E), and 100 ug of pVAX1-HA2-fimA+CpG-ODN 1826 (30 μg) (group F), respectively. Asterisk represents a significant difference between group F and the other groups, respectively, *P < 0.05

Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us